Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$3.82 -0.5%	$3.57	$2.12 ▼ $5.80	$379.43M	1.99	1.09 million shs	941,366 shs
CLYM Climb Bio	$1.45 +3.6%	$1.32	$1.05 ▼ $8.79	$97.99M	-0.11	204,297 shs	145,674 shs
ETON Eton Pharmaceuticals	$14.13 -0.2%	$15.29	$3.25 ▼ $21.48	$378.94M	1.13	425,198 shs	249,492 shs
ITOS iTeos Therapeutics	$10.09 -0.5%	$10.05	$4.80 ▼ $18.13	$386.18M	1.49	1.44 million shs	1.54 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	0.00%	-7.95%	+2.69%	+27.33%	-0.52%
CLYM Climb Bio	0.00%	0.00%	+13.28%	+14.17%	+144,999,900.00%
ETON Eton Pharmaceuticals	0.00%	-8.25%	-2.72%	-18.51%	+292.50%
ITOS iTeos Therapeutics	0.00%	-0.79%	-0.79%	+29.86%	-42.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQST Aquestive Therapeutics	1.7021 of 5 stars	3.5	3.0	1.9	0.0	0.0
CLYM Climb Bio	2.3381 of 5 stars	3.6	0.0	0.0	2.5	1.3
ETON Eton Pharmaceuticals	1.8788 of 5 stars	3.5	1.0	1.6	1.7	0.6
ITOS iTeos Therapeutics	2.924 of 5 stars	4.1	2.0	0.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	3.00	Buy	$10.14	165.52% Upside
CLYM Climb Bio	3.25	Buy	$9.00	520.69% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	109.96% Upside
ITOS iTeos Therapeutics	2.14	Hold	$15.64	55.03% Upside

Current Analyst Ratings Breakdown

Latest CLYM, ETON, AQST, and ITOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2025	ITOS iTeos Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/21/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$12.00 ➝ $10.50
6/17/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/6/2025	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
6/2/2025	AQST Aquestive Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00
5/28/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$13.00 ➝ $12.00
5/28/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $12.00
5/22/2025	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/22/2025	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$7.00
5/16/2025	ETON Eton Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $26.00

(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$57.56M	6.59	N/A	N/A	($0.66) per share	-5.79
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.15 per share	N/A
ETON Eton Pharmaceuticals	$39.01M	9.71	N/A	N/A	$0.94 per share	15.03
ITOS iTeos Therapeutics	$35M	11.03	N/A	N/A	$16.16 per share	0.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$44.14M	-$0.59	N/A	N/A	N/A	-100.02%	N/A	-50.31%	8/5/2025 (Estimated)
CLYM Climb Bio	-$73.90M	-$2.38	N/A	N/A	N/A	N/A	-43.95%	-42.94%	8/13/2025 (Estimated)
ETON Eton Pharmaceuticals	-$3.82M	-$0.18	N/A	28.26	N/A	-9.49%	-3.15%	-1.08%	8/7/2025 (Estimated)
ITOS iTeos Therapeutics	-$134.41M	-$3.04	N/A	N/A	N/A	N/A	-21.37%	-18.55%	8/6/2025 (Estimated)

Latest CLYM, ETON, AQST, and ITOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ITOS iTeos Therapeutics	-$0.94	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	CLYM Climb Bio	-$0.19	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	ETON Eton Pharmaceuticals	-$0.02	N/A	N/A	N/A	$16.71 million	N/A
8/5/2025	Q2 2025	AQST Aquestive Therapeutics	-$0.18	N/A	N/A	N/A	$11.32 million	N/A
5/14/2025	Q1 2025	CLYM Climb Bio	-$0.15	-$0.31	-$0.16	-$0.31	N/A	N/A
5/13/2025	Q1 2025	ETON Eton Pharmaceuticals	$0.09	$0.07	-$0.02	-$0.06	$14.33 million	$17.28 million
5/12/2025	Q1 2025	AQST Aquestive Therapeutics	-$0.17	-$0.24	-$0.07	-$0.24	$12.23 million	$8.72 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	4.87	4.48
CLYM Climb Bio	N/A	14.25	14.25
ETON Eton Pharmaceuticals	1.23	1.97	1.43
ITOS iTeos Therapeutics	N/A	14.13	14.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
CLYM Climb Bio	69.76%
ETON Eton Pharmaceuticals	27.86%
ITOS iTeos Therapeutics	97.16%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	8.35%
CLYM Climb Bio	0.80%
ETON Eton Pharmaceuticals	16.03%
ITOS iTeos Therapeutics	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	99.33 million	91.03 million	Optionable
CLYM Climb Bio	9	67.58 million	67.04 million	N/A
ETON Eton Pharmaceuticals	20	26.82 million	22.52 million	Optionable
ITOS iTeos Therapeutics	90	38.27 million	33.49 million	Optionable

CLYM, ETON, AQST, and ITOS Headlines

Recent News About These Companies

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives $15.64 Consensus PT from Brokerages

August 2 at 2:43 AM | americanbankingnews.com

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives Average Rating of "Hold" from Analysts

July 28, 2025 | marketbeat.com

Wedbush Predicts Lower Earnings for iTeos Therapeutics

July 26, 2025 | americanbankingnews.com

Readystate Asset Management LP Sells 26,114 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

July 25, 2025 | marketbeat.com

Q2 EPS Estimate for iTeos Therapeutics Lowered by Analyst

July 25, 2025 | americanbankingnews.com

Q2 EPS Estimate for iTeos Therapeutics Decreased by Analyst

July 24, 2025 | marketbeat.com

Q2 EPS Estimates for iTeos Therapeutics Cut by Wedbush

July 24, 2025 | marketbeat.com

iTeos Therapeutics accepts takeover bid from Concentra

July 23, 2025 | thepharmaletter.comT

Piper Sandler Downgrades iTeos Therapeutics (NASDAQ:ITOS) to Hold

July 23, 2025 | marketbeat.com

Wedbush Reaffirms Outperform Rating for iTeos Therapeutics (NASDAQ:ITOS)

July 21, 2025 | marketbeat.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders

July 21, 2025 | globenewswire.com

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of iTeos Therapeutics, Inc.

July 21, 2025 | prnewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of iTeos Therapeutics, Inc. (NASDAQ: ITOS)

July 21, 2025 | globenewswire.com

ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders

July 21, 2025 | tmcnet.com

iTeos Therapeutics to be acquired by Concentra Biosciences

July 21, 2025 | msn.com

iTeos Therapeutics, Inc. Enters Merger Agreement with Concentra Biosciences, LLC for $10.047 per Share Acquisition

July 21, 2025 | quiverquant.comQ

iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right

July 21, 2025 | globenewswire.com

Peapod Lane Capital LLC Increases Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

July 10, 2025 | marketbeat.com

iTeos Therapeutics (ITOS): An Example of Biotech Liquidations

July 9, 2025 | finance.yahoo.com

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Consensus Recommendation of "Hold" by Brokerages

July 3, 2025 | marketbeat.com

ITOS iTeos Therapeutics, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM, ETON, AQST, and ITOS Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$3.82 -0.02 (-0.52%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$3.84 +0.02 (+0.55%)

As of 08/1/2025 07:55 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Climb Bio NASDAQ:CLYM

$1.45 +0.05 (+3.57%)

As of 08/1/2025 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Eton Pharmaceuticals NASDAQ:ETON

$14.13 -0.03 (-0.21%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$14.12 -0.01 (-0.07%)

As of 08/1/2025 06:20 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

iTeos Therapeutics NASDAQ:ITOS

$10.09 -0.05 (-0.49%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$10.10 +0.01 (+0.05%)

As of 08/1/2025 04:04 PM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time